XML 34 R20.htm IDEA: XBRL DOCUMENT
v3.25.3

Note 3 - Summary of Significant Accounting Policies (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Notes Tables |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] |
|  | September 30, |
|  | 2025 |  |  | 2024 |
Common stock warrants |  |  | 2,601,671 |  |  |  | 2,633,868 |
Stock options |  |  | 995,374 |  |  |  | 533,159 |
|  |  | 3,597,045 |  |  |  | 3,167,027 |
Schedule of Segment Reporting Information, by Segment [Table Text Block] |
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Grant revenue |  | $ | 322,569 |  |  | $ | 1,939,751 |  |  | $ | 3,997,784 |  |  | $ | 7,575,972 |
Research and development expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Dementia with Lewy bodies |  |  | 1,680,922 |  |  |  | 3,317,345 |  |  |  | 5,866,430 |  |  |  | 8,753,991 |
Frontotemporal dementia |  |  | 313,438 |  |  |  | 2,581 |  |  |  | 846,664 |  |  |  | 2,581 |
Recovery after stroke |  |  | 396,635 |  |  |  | 112,759 |  |  |  | 952,338 |  |  |  | 112,759 |
Other clinical* and preclinical |  |  | 485,586 |  |  |  | 541,125 |  |  |  | 1,505,726 |  |  |  | 542,932 |
Personnel costs, excluding stock-based compensation |  |  | 1,767,086 |  |  |  | 643,024 |  |  |  | 4,060,722 |  |  |  | 1,235,556 |
Stock-based compensation |  |  | 133,169 |  |  |  | 42,224 |  |  |  | 378,029 |  |  |  | 146,358 |
Other research and development expenses, including CMC** |  |  | 1,263,606 |  |  |  | 466,039 |  |  |  | 2,376,956 |  |  |  | 917,569 |
Total research and development expenses |  |  | 6,040,442 |  |  |  | 5,125,097 |  |  |  | 15,986,865 |  |  |  | 11,711,746 |
General and administrative expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Personnel costs, excluding stock-based compensation |  |  | 1,087,467 |  |  |  | 1,168,151 |  |  |  | 3,797,765 |  |  |  | 2,968,276 |
Stock-based compensation |  |  | 158,548 |  |  |  | 22,050 |  |  |  | 771,869 |  |  |  | 921,653 |
Professional fees |  |  | 711,307 |  |  |  | 707,725 |  |  |  | 2,053,984 |  |  |  | 2,049,828 |
Insurance, taxes and similar fees |  |  | 258,032 |  |  |  | 241,123 |  |  |  | 917,616 |  |  |  | 709,178 |
Other general and administrative expenses, including IT, facilities, supplies and similar costs*** |  |  | 110,972 |  |  |  | 71,878 |  |  |  | 433,043 |  |  |  | 201,601 |
Total general and administrative expenses |  |  | 2,326,326 |  |  |  | 2,210,927 |  |  |  | 7,974,277 |  |  |  | 6,850,536 |
Other income |  |  | 317,560 |  |  |  | 642,732 |  |  |  | 1,084,281 |  |  |  | 1,401,529 |
Net loss |  | $ | (7,726,639 | ) |  | $ | (4,753,541 | ) |  | $ | (18,879,077 | ) |  | $ | (9,584,781 | )

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration